abt 702 has been researched along with Alloxan Diabetes in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was undertaken to determine the effect of an adenosine kinase inhibitor (AKI) in diabetic retinopathy (DR)." | 7.79 | ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. ( Ahmad, S; Al-Gayyar, MM; Eissa, LA; El-Shishtawy, MM; Elsherbini, AM; Elsherbiny, NM; Fulzele, S; Liou, GI; Naime, M, 2013) |
| "This study was undertaken to determine the effect of an adenosine kinase inhibitor (AKI) in diabetic retinopathy (DR)." | 3.79 | ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. ( Ahmad, S; Al-Gayyar, MM; Eissa, LA; El-Shishtawy, MM; Elsherbini, AM; Elsherbiny, NM; Fulzele, S; Liou, GI; Naime, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elsherbiny, NM | 2 |
| Ahmad, S | 1 |
| Naime, M | 1 |
| Elsherbini, AM | 1 |
| Fulzele, S | 1 |
| Al-Gayyar, MM | 1 |
| Eissa, LA | 1 |
| El-Shishtawy, MM | 1 |
| Liou, GI | 2 |
| Pye, C | 1 |
| Ibrahim, AS | 1 |
| Chadli, A | 1 |
| Al-Shabrawey, M | 1 |
| Elmarakby, AA | 1 |
| Kowaluk, EA | 1 |
| Mikusa, J | 1 |
| Wismer, CT | 1 |
| Zhu, CZ | 1 |
| Schweitzer, E | 1 |
| Lynch, JJ | 1 |
| Lee, CH | 1 |
| Jiang, M | 1 |
| Bhagwat, SS | 1 |
| Gomtsyan, A | 1 |
| McKie, J | 1 |
| Cox, BF | 1 |
| Polakowski, J | 1 |
| Reinhart, G | 1 |
| Williams, M | 1 |
| Jarvis, MF | 1 |
3 other studies available for abt 702 and Alloxan Diabetes
| Article | Year |
|---|---|
ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Adenosine Kinase; Animals; Cells, Cultured; Diabetes M | 2013 |
Adenosine kinase inhibition protects the kidney against streptozotocin-induced diabetes through anti-inflammatory and anti-oxidant mechanisms.
Topics: Adenosine Kinase; Animals; Anti-Inflammatory Agents; Antioxidants; Blood Glucose; Cell Line; Dextran | 2014 |
ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat.
Topics: Adenosine Kinase; Administration, Oral; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, | 2000 |